SoftOx Solutions is trading 5% down at NOK 0.09 amid broader risk-off conditions, with no new company-specific announcement identified for September 2, 2026.
- The decline appears consistent with September 1 losses in major equity markets, geopolitical tensions, higher oil prices, and rising bond yields.
- The first patient dosed in the SIS-03 proof-of-concept trial predates the move and does not directly explain the September 2 decline.